Kenvue Inc. Common Stock vs Neurocrine Biosciences Inc — how do they compare? Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Kenvue Inc. Common Stock is far larger — about 2.4× Neurocrine Biosciences Inc's market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| KVUE | NBIX | |
|---|---|---|
Market Cap | $34.06B | $14.36B |
Volume | 23,267,228 | 1,237,180 |
Sector | Consumer Staples | Health |
52-Week High | $19.83 | $185.50 |
52-Week Low | $14.11 | $123.10 |
Enterprise Value | $41.56B | $14.37B |
Dividend Yield | 4.74% | — |
Typical Hold Time | — | 23 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →